- Home
- NBBK vs ORIC Comparison
NBBK vs ORIC Comparison
Compare NBBK & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBBK | ORIC |
|---|---|---|
| Founded | 1892 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 889.5M | 837.3M |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NBBK | ORIC |
|---|---|---|
| Price | $20.19 | $8.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | ★ $23.50 | $19.73 |
| AVG Volume (30 Days) | 356.1K | ★ 1.4M |
| Earning Date | 04-22-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.43% | N/A |
| EPS Growth | ★ 25.23 | 19.67 |
| EPS | ★ 1.34 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $45.15 | N/A |
| Revenue Next Year | $4.18 | N/A |
| P/E Ratio | $15.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.44 | $4.65 |
| 52 Week High | $22.86 | $14.93 |
Technical Indicators
Market Signals| Indicator | NBBK | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 43.72 | 36.43 |
| Support Level | $19.87 | $7.90 |
| Resistance Level | $20.63 | $11.22 |
| Average True Range (ATR) | 0.60 | 0.55 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 42.32 | 6.47 |
Price Performance
Historical ComparisonAbout NBBK NB Bancorp Inc.
NB Bancorp Inc operates as the holding company of Needham Bank. The group's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, consumer loans, and other related services.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.